What's Happening?
Amylyx Pharmaceuticals has decided to halt the clinical development of AMX0035 for progressive supranuclear palsy (PSP) after the drug failed to show significant efficacy in the Phase IIb/III ORION trial. The trial did not meet its primary endpoint of disease progression improvement, leading to the termination of the open-label extension phase.
Why It's Important?
The discontinuation of AMX0035 for PSP highlights the challenges in developing treatments for rare neurodegenerative disorders. This decision may impact Amylyx's strategic focus and resource allocation, while also influencing the broader landscape of PSP research and drug development.
AD
